INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 21, 2026 [2]. - The lawsuit follows a significant stock price drop after the FDA issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, which was intended for treating hypertension secondary to hypercortisolism [4]. Group 2: Stock Performance - Following the FDA's announcement, Corcept's stock price fell by $35.40 per share, representing a 50.4% decrease, closing at $34.80 per share on December 31, 2025 [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].